Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A

被引:114
作者
Razai, A
Garcia-Rodriguez, C
Lou, J
Geren, IN
Forsyth, CM
Robles, Y
Tsai, R
Smith, TJ
Smith, LA
Siegel, RW
Feldhaus, M
Marks, JD
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Anesthesia & Pharmaceut Chem, San Francisco, CA 94110 USA
[2] USA, Med Res Inst Infect Dis, Toxinol Div, Frederick, MD 21701 USA
[3] Pacific NW Natl Lab, Richland, WA 99352 USA
关键词
yeast display; single chain Fv antibody; molecular evolution; botulinum neurotoxin; affinity;
D O I
10.1016/j.jmb.2005.06.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Botulism is caused by botulinum neurotoxin (BoNT), the most poisonous substance known. Potential use of BoNT as a biothreat agent has made development of sensitive assays for toxin detection and potent antitoxin for treatment of intoxication a high priority. To improve detection and treatment of botulism, molecular evolution and yeast display were used to increase the affinity of two neutralizing single chain Fv (scFv) antibodies binding BoNT serotype A (BoNT/A). Selection of yeast displayed scFv libraries was performed using methods to select for both increased association rate constant (k(on)) and decreased dissociation rate constants (k(off)). A single cycle of error prone mutagenesis increased the affinity of the 3D12 scFv 45-fold from a K-D of 9.43X10(-10) M to a K-D of 2.1 X 10(-11) M. Affinity of the HuC25 scFv was increased 37-fold from 8.44 X 10(-10) M to 2.26 X 10(-11) M using libraries constructed by both random and site directed mutagenesis. scFv variable region genes were used to construct IgG for use in detection assays and in vivo neutralization studies. While IgG had the same relative increases in affinity as scFv, (35-fold and 81-fold, respectively, for 3D12 and HuC25) higher solution equilibrium binding constants were observed for the IgG, with the 3D12 KD increasing from 6.07 X 10(-11) M to 1.71 X 10(-12) M and the HuC25 K-D increasing from 4.51 X 10(-11) M to 5.54 X 10(-13) M. Affinity increased due to both an increase in k(on), as well as slowing of k(off). Higher affinity antibodies had increased sensitivity, allowing detection of BoNT/A at concentrations as low as 1 X 10(-13) M. The antibodies will also allow testing of the role of affinity in in vivo toxin neutralization and could lead to the generation of more potent antitoxin. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:158 / 169
页数:12
相关论文
共 45 条
[1]   Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries [J].
Amersdorfer, P ;
Wong, C ;
Chen, S ;
Smith, T ;
Deshpande, S ;
Sheridan, R ;
Finnern, R ;
Marks, JD .
INFECTION AND IMMUNITY, 1997, 65 (09) :3743-3752
[2]   Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries [J].
Amersdorfer, P ;
Wong, C ;
Smith, T ;
Chen, S ;
Deshpande, S ;
Sheridan, R ;
Marks, JD .
VACCINE, 2002, 20 (11-12) :1640-1648
[3]  
Amon S. S., 2001, JAMA-J AM MED ASSOC, V285, P1059
[4]  
ARNON SS, 1993, BOTULINUM AND TETANUS NEUROTOXINS, P477
[5]  
BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.bb.14.060185.001023
[6]   HYPERSENSITIVITY REACTIONS ASSOCIATED WITH BOTULINAL ANTITOXIN [J].
BLACK, RE ;
GUNN, RA .
AMERICAN JOURNAL OF MEDICINE, 1980, 69 (04) :567-570
[7]   Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution [J].
Blake, RC ;
Pavlov, AR ;
Blake, DA .
ANALYTICAL BIOCHEMISTRY, 1999, 272 (02) :123-134
[8]   Yeast surface display for directed evolution of protein expression, affinity, and stability [J].
Boder, ET ;
Wittrup, KD .
APPLICATIONS OF CHIMERIC GENES AND HYBRID PROTEINS, PT C: PROTEIN-PROTEIN INTERACTIONS AND GENOMICS, 2000, 328 :430-444
[9]   Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate [J].
Byrne, MP ;
Smith, TJ ;
Montgomery, VA ;
Smith, LA .
INFECTION AND IMMUNITY, 1998, 66 (10) :4817-4822
[10]  
CDC, 1998, Botulism in the United States, 1899-1996 Handbook for Epidemiologists, Clinicians, and Laboratory Workers